RNS Number : 8357E MaxCyte, Inc. 12 July 2021 MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing GAITHERSBURG, MD , July 12, 2021 - MaxCyte, Inc. , (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering,
RNS Number : 8366E MaxCyte, Inc. 12 July 2021 Financial information in the Form S-1 registration statement & Change to Board of Directors GAITHERSBURG, MD , 12 July 2021 - MaxCyte, Inc. , (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering ("
RNS Number : 3656E MaxCyte, Inc. 06 July 2021 Result of Special Meeting GAITHERSBURG, MD , 06 July 2021 - MaxCyte, Inc. , (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering, announces that at the Special Meeting held earlier today in respect of the
RNS Number : 0186C MaxCyte, Inc. 16 June 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Publication of Annual Report and Accounts Gaithersburg, Maryland - 16 June 2021 : MaxCyte (LSE: MXCT, MXCN), a leading provider of cell-engineering platform
RNS Number : 0185C MaxCyte, Inc. 16 June 2021 Publication of Stockholder Circular and Notice of Special Meeting Gaithersburg, Maryland - 16 June 2021 : MaxCyte (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering, today announced that it has published a
RNS Number : 8666B MaxCyte, Inc. 15 June 2021 MaxCyte Adds Two New Non-Executive Directors to Its Board Gaithersburg, Maryland - 15 June 2021 : MaxCyte (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering, today announced the appointment of Rekha Hemrajani
RNS Number : 5575A MaxCyte, Inc. 02 June 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 2 June 2021 : MaxCyte (LSE: MXCT, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block admission
RNS Number : 6449Z MaxCyte, Inc. 25 May 2021 FOR IMMEDIATE RELEASE Celularity and MaxCyte Sign Strategic Platform Licence to Advance Celularity's Off-the-shelf Allogeneic Cellular Therapy Product Candidates Celularity to utilize MaxCyte's Flow Electroporation ® technology and ExPERT ™
RNS Number : 6562Y MaxCyte, Inc. 14 May 2021 Proposed Dual-Listing on Nasdaq This announcement contains inside information Gaithersburg, Maryland - May 14, 2021 - MaxCyte, Inc. (LSE: MXCT, MXCL, MXCN) (" MaxCyte " or the " Company "), a leading provider of platform technologies for cell
RNS Number : 4604Y MaxCyte, Inc. 13 May 2021 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR
